Novo Nordisk's Oral Wegovy Breaks Records, but Generics Threaten to Undercut the Party

Novo Nordisk's oral Wegovy pill generated 2.26B DKK in Q1, doubling analyst estimates, but generic semaglutide launches in India and Canada threaten pricing power and market share.

Novo Nordisk’s bet on a pill version of Wegovy is paying off handsomely — and then some. The oral formulation generated 2.26 billion Danish kroner in first-quarter sales, more than double what analysts had penciled in. That blockbuster performance helped lift group revenue to 96.8 billion kroner, a currency-adjusted increase of 32% from a year earlier.

Yet beneath the headline beats a more complicated pulse. The Copenhagen-based drugmaker is grappling with two opposing forces: a booming GLP-1 franchise that keeps winning new patients, and a gathering generic storm that threatens to erode pricing power in some of the world’s fastest-growing markets.

A Pill That Defied Expectations

The Wegovy tablet, launched in late 2025, has already racked up over two million prescriptions in the United States. Doctors are embracing the convenience of an oral alternative to injections, and the company’s decision to partner with Amazon for same-day home delivery has widened access further. In the first quarter alone, more than one million patients started treatment within 16 weeks of the pill’s debut.

Rival Eli Lilly’s oral contender, Foundayo, managed only 5,600 prescriptions in its third week — a fraction of Novo Nordisk’s pace. The Dane now controls roughly 65% of new prescription volume in the fast-growing oral GLP-1 segment.

The blistering start has forced management to revise its full-year outlook. Adjusted revenue and operating profit are now expected to shrink by 4% to 12%, an improvement over the prior forecast. Still, that means a contraction, not expansion — a reality that tempers any euphoria.

Generic Bombshells Are Dropping

The clearest threat comes from copycat versions of semaglutide, the active ingredient in both Wegovy and Ozempic. In India, the patent expired on March 20, 2026, and regulators have already cleared Sun Pharma, Zydus, and Alkem to sell their own products. Sun Pharma’s version is priced significantly below the original.

Canada and Brazil are next. Health Canada approved a first semaglutide generic from Dr. Reddy’s on April 28, 2026, and Apotex followed on May 1. Sandoz plans to launch in both countries later in 2026. Analysts see the Swiss generics player generating double-digit millions in sales during the first year, potentially rising to $742.6 million by 2035.

That kind of competition could squeeze margins and market share in key emerging markets, forcing Novo Nordisk to rely even more heavily on its brand power and delivery channel innovations.

FDA May Help — But Only a Little

The U.S. regulatory landscape offers some relief. On April 30, the Food and Drug Administration proposed removing semaglutide, tirzepatide, and liraglutide from the 503B compounding list. If enacted, the rule would sharply limit pharmacies from mixing their own unapproved versions, protecting official brand-name products from a parallel gray market that has grown steadily.

Meanwhile, the Medicare GLP-1 Bridge Program is set to launch in July 2026. Eligible enrollees will pay just $50 per month for Wegovy — both injection and tablet — through the end of 2027. That could unlock a fresh wave of demand among older Americans who previously faced high out-of-pocket costs.

Stock Story: Recovery Without Euphoria

Investors have taken notice. Novo Nordisk shares have rallied 21.5% over the past month, closing at €39.02 on Friday. Yet the stock remains well below its year-ago levels, down roughly 33% over the past twelve months and 12.67% since January.

Technically, the picture is mixed. The stock sits above its 50-day moving average of €33.48 but below the 200-day average of €42.48 — a classic sign of a downtrend still intact. The average analyst price target for the U.S. ADR stands at $47.31, with a consensus rating of Hold.

The next major catalyst arrives this week. Starting May 12, the European Congress on Obesity in Istanbul will feature 52 abstracts from Novo Nordisk, including head-to-head data comparing the Wegovy pill against Lilly’s orforglipron. Early studies have favored the Danish compound, and investors will be watching for confirmation.

What Lies Ahead

The July start of the Medicare program should provide a near-term volume boost, but the generic incursions in Canada and Brazil later in 2026 will test Novo Nordisk’s pricing discipline. The company’s decision to expand its own distribution — via the Amazon tie-up, a new Ozempic pill launched in the U.S. in early May, and a focus on oral formulations — shows it is not standing still.

Still, the fundamental tension remains. Novo Nordisk is riding a wave of innovation and access, yet the patent cliff is inching closer. For now, the pill is winning. The question is how long that can last.